
|Videos|January 27, 2022
Trends in the ASCVD, LDL-C Management Treatment Landscape in 2022
Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses major trends in the atherosclerotic cardiovascular disease and LDL-C management treatment landscape this year.
Advertisement
Pharmacy Times interviewed Norman Lepor, MD, a Los Angeles-based cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), on the burden of atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol (LDL-C) management.
During the interview, Lepor discussed some of the major trends in the ASCVD and LDL-C management treatment landscape this year.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
Subcutaneous Isatuximab On-Body Injector Shows High Reliability, Favorable Safety Across Multiple Myeloma Trials
3
Real-World Use of Talazoparib Plus Enzalutamide and HR Testing Trends in Prostate Cancer
4
Alzheimer Updates, Stroke Breakthroughs, and the Case for Early Treatment
5




























































































































